Biotech sector needs to embrace economic reality, says Amgen
4 March 2009
The biopharmaceutical industry must embrace the challenges posed by
the current financial downturn and transform its way of conducting
business in order to survive, says Dr Ran Zheng, Plant Manager of
Clinical Operations at Amgen and forthcoming speaker at Informa’s
BioProcess International (BPI) European Conference and Exhibition in
Dusseldorf, in April 2009.
“After years of growth and prosperity, biopharmaceutical companies
must now embrace this new reality,” said Dr Zheng in an exclusive
interview for the event, stressing the importance of operational
excellence and innovative technologies as the way forward.
“Companies have come to realise operational excellence as a strategy,
and discipline will help to improve quality, yield and throughput;
reduce waste, inconsistency and unpredictability of operations,
ultimately helping companies achieve greater profitability.
The Conference includes five co-located conferences and tackles the
latest issues in: Scale-Up, Economics and Manufacturing Strategies;
Formulation; Recovery and Purification; Cell Culture and Upstream
Processing; and Analytical Methods.
For more information see:
Bookmark this page